Cysteine-Engineered Elastin-Like Polypeptide Hydrogels for Rapid Photocrosslinking

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Elastin-like polypeptides (ELPs) based biomaterials have limitations in terms of elasticity and mechanical properties compared to synthetic polymeric scaffolds, requiring chemical modification and long crosslinking times for 3D scaffold formation, which can generate toxic byproducts and hinder rapid gelation necessary for clinical applications.

Innovation Solution

Engineered polypeptides with cysteine residues for disulfide bond formation, allowing for rapid photocrosslinking to create biocompatible hydrogels with tunable mechanical properties, including high extensibility and rapid polymerization, using a photoinitiator under light irradiation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Strength

If chemical crosslinking methods (NHS reactions, glutaraldehyde) are used to form 3D ELP scaffolds, then mechanical stability and structural integrity are improved, but crosslinking time increases and toxic byproducts are generated

Engineering Contradiction:
Improvemechanical stabilityVSAvoidcrosslinking time
Core Design Contradiction:
StrengthVSLoss of time

Solution Approach 1:

The patent replaces chemical crosslinking mechanisms (NHS reactions, glutaraldehyde crosslinking) with photocrosslinking using UV irradiation and photoinitiators. This substitution enables rapid crosslinking (seconds to minutes versus hours) while eliminating toxic byproduct generation, directly resolving the contradiction between mechanical stability and crosslinking time/toxicity

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent modifies the ELP protein sequence to incorporate cysteine residues at specific positions, changing the chemical parameters of the polymer. These cysteine residues enable disulfide bond formation under UV light, transforming the crosslinking mechanism from slow chemical reactions to rapid photo-induced bond formation, achieving both speed and mechanical integrity

Inventive Principle:
Principle #35Parameter changes

2Stability of the object's composition

If chemical modification and long crosslinking time are used for 3D scaffold formation, then structural integrity is improved, but capability for rapid gelation and 3D cell encapsulation is hindered

Engineering Contradiction:
Improvestructural integrityVSAvoidrapid gelation capability
Core Design Contradiction:
Stability of the object's compositionVSProductivity

Solution Approach 1:

The patent substitutes chemical crosslinking with photocrosslinking, enabling structural integrity to be achieved in seconds to minutes rather than hours. This rapid gelation capability allows for 3D cell encapsulation before the cells are exposed to toxic chemical crosslinkers, resolving the contradiction between structural integrity and productivity

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent performs cell encapsulation in the liquid ELP solution before initiating photocrosslinking. The cells are positioned and distributed in three dimensions within the scaffold precursors, and then rapid UV-induced crosslinking locks the structure in place. This preliminary action enables both rapid gelation and proper 3D cell positioning

Inventive Principle:
Principle #10Preliminary action

3Stability of the object's composition

If chemical crosslinking is used to form stable gels, then gel stability is improved, but biocompatibility and reduced toxicity are compromised

Engineering Contradiction:
Improvegel stabilityVSAvoidtoxicity
Core Design Contradiction:
Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent replaces chemical crosslinking systems (NHS esters, glutaraldehyde) that generate toxic byproducts with a photocrosslinking system using UV irradiation and photoinitiators. This substitution maintains gel stability through disulfide bond formation while eliminating toxicity, as the photocrosslinking process does not generate harmful chemical byproducts

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces cysteine residues as intermediary functional groups in the ELP sequence. These cysteine residues mediate crosslinking through disulfide bond formation when exposed to UV light, serving as a safe intermediary that enables stable gel formation without requiring toxic chemical crosslinkers

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The resulting hydrogels exhibit enhanced mechanical properties such as high extensibility and rapid crosslinking, suitable for tissue engineering and wound healing applications, with improved biocompatibility and reduced toxicity, enabling their use in soft and elastic tissues like skin, blood vessels, and cardiac tissues.

Implementation Method 1

Engineered polypeptides with cysteine residues for disulfide bond formation

Methodology Applied
Scientific EffectDisulfide bond formation: Oxidation

Implementation Method 2

rapid photocrosslinking to create biocompatible hydrogels... using a photoinitiator under light irradiation

Methodology Applied
Scientific EffectPhotopolymerization: Photopolymerisation

Data Source

PatentEP3270985B1Polypeptide compositions and methods of using the same
Publication Date: 2021.02.24 THE BRIGHAM & WOMEN S HOSPITAL INC
  • EP3270985B1 patent drawingFigure 1(a)~1(d)
  • EP3270985B1 patent drawingFigure 2(a)~2(f)
  • EP3270985B1 patent drawingFigure 3(a)~3(g)

AI summary

Disclosed herein are polypeptides comprising an amino acid sequence of {[VPGVG]4IPGVG}n, wherein n is an integer greater than 1. The polypeptides can be crosslinked to from biocompatible hydrogels with tunable and desirable mechanical properties. The polypeptides and hydrogels can be used in a variety of biomedical applications including treatment of bleeding, treatment of soft tissue injury, injectable filler, and tissue adhesives.